Bioresorbable has designed a bioresorbable stent for PVD patients. Credit: Arterius Limited

Arterius has partnered with the University of Bristol’s Translational Biomedical Research Centre (TBRC) to develop a smart bioresorbable stent for severe peripheral vascular disease (PVD).

The two-year project has secured £1.1m in funding from Innovate UK.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Featuring mechanical and biocompatible properties, the stent will be designed to treat blockages associated with PVD and be absorbed into the body within 18-24 months.

PVD is currently treated with metal stents, which are permanently inserted into a blocked artery. These devices may cause blood clotting and long-term chronic inflammation at the site, which often cause blockages to reoccur within one to two years and lead to readmissions, repeated revascularisation and increased hospital costs.

“Our primary goal of this consortium is to develop bioresorbable smart stents for pre-clinical assessment in carotid and iliac-femoral arteries.”

The new stent is designed to avoid the life-long presence of metal stents and their related complications.

TBRC director Raimondo Ascione said: “There is a huge need for innovation based on rigorous preclinical development and testing in the area of severe peripheral vascular disease. We are delighted to join forces with Arterius to form a unique UK-based biomedical consortium with the potential to be a global player in this field.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The partners intend to develop a prototype of the smart bioresorbable stent and assess its safety and efficacy using clinical and imaging technologies available at TBRC’s preclinical facility.

They plan to begin first-in-human clinical trials within three to four years.

Ascione and Arterius CEO Kadem Al-Lamee added: “Our primary goal of this consortium is to develop bioresorbable smart stents for pre-clinical assessment in carotid and iliac-femoral arteries, as well as a platform technology, which we plan to use to tackle in the future other areas of peripheral vascular disease such as below the knee, given the high level of biomedical innovation.”

Severe PVD is known to affect approximately 20% of people aged 55–80 years in the UK, and 200 million people worldwide.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now